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Introduction {#sec001}
============

Cholesterol is essential for the regulation of biological functions in animals. In cell membranes, cholesterol enhances fluidity, reduces permeability and is a constituent of lipid rafts \[[@pgen.1008628.ref001]\]. Moreover, cholesterol or its intermediates are precursors of vitamin D, steroid hormones, and bile acids. Cholesterol itself alters the activity of proteins such as sonic hedgehog (Shh) \[[@pgen.1008628.ref002]\]\[[@pgen.1008628.ref003]\] which is involved in embryogenesis and tissue growth. In the cholesterol synthesis pathway, beginning with acetyl-CoA, lanosterol synthase (LSS) converts (S)-2,3-epoxysqualene to lanosterol \[[@pgen.1008628.ref004]\] ([S1 Fig](#pgen.1008628.s001){ref-type="supplementary-material"}). Biallelic mutations in *LSS* were first reported in families with congenital cataracts \[[@pgen.1008628.ref005],[@pgen.1008628.ref006]\]. In addition, very recently, hypotrichosis has been reported to be an associated phenotype with biallelic *LSS* mutations \[[@pgen.1008628.ref007],[@pgen.1008628.ref008]\]. Out of 24 patients, all had either cataracts (5/24) or hypotrichosis (20/24), and one had both \[[@pgen.1008628.ref005]--[@pgen.1008628.ref008]\]. Thus, cataracts and hypotrichosis are core symptoms in patients with biallelic *LSS* mutations. However, the pathophysiology in patients largely remains to be clarified. First, it is not proven that biallelic *LSS* mutations cause LSS deficiency because the metabolite profiles in the previously reported patients have not been compatible with LSS enzymatic dysfunctions. The cholesterol or the intermediate levels in serum or plasma did not significantly change between the patients and controls \[[@pgen.1008628.ref007],[@pgen.1008628.ref008]\]. Second, animal models that reproduce the LSS-deficient state remain to be developed. Although the Shumiya cataract rat has biallelic *Lss* mutations \[[@pgen.1008628.ref009]\], this rat has additional mutations in *Fdft1*, which encodes an upstream enzyme in the cholesterol synthetic pathway. Moreover, the metabolic profiles of the lens were inconsistent with LSS enzymatic inhibition in the Shumiya cataract rat. There is no report of model mice that reproduce cataract or hypotrichosis due to the embryonic lethality of the *Lss* null mice \[[@pgen.1008628.ref010]\]. Collectively, it has not been established whether biallelic *LSS* mutations cause LSS enzymatic deficiency and the local symptoms in each tissue or if they lead to systemic effects on abnormal metabolites, and this is due to the lack of an appropriate model animal and the difficulty in measuring metabolites of the LSS enzyme.

Here, we report two siblings with novel biallelic *LSS* mutations who presented congenital hypotrichosis, midline anomalies, such as cleft palate and agenesis of the corpus callosum, and no cataracts. The aims of this study were to confirm an LSS enzymatic disruption, that is, the presence of LSS deficiency, in patients with biallelic *LSS* mutation and to create *Lss*-deficient mice to elucidate whether LSS enzymatic depletion in each tissue is responsible for the symptoms in that tissue.

Results {#sec002}
=======

Clinical information of patients with congenital hypotrichosis and anomalies {#sec003}
----------------------------------------------------------------------------

We studied two sibling patients with congenital hypotrichosis and several anomalies ([Fig 1a](#pgen.1008628.g001){ref-type="fig"}). The parents and the first child had no medical problems, including congenital anomalies. The first patient (patient II-2) was the second boy in a nonconsanguineous Japanese family ([Fig 1b](#pgen.1008628.g001){ref-type="fig"}). This patient was delivered at 36 weeks of gestation due to low amniotic fluid and fetal growth restriction (FGR). His birth weight was 1,848 g (-2.26 SD), and height was 42.0 cm (-2.03 SD). At birth, mild ichthyosis was observed on his chest, abdomen, back, and upper extremities ([S2 Fig](#pgen.1008628.s002){ref-type="supplementary-material"}). This ichthyosis disappeared by the age of 2 months. His body hair never grew despite treatment, such as topical vitamin D and steroid therapy. He had intermittent exotropia, hypospadias and partial agenesis of the corpus callosum ([S3 Fig](#pgen.1008628.s003){ref-type="supplementary-material"}). At the most recent follow-up (18 years old), his height was 157.1 cm (-2.35 SD), and his body weight was 66.1 kg (0.54 SD), showing significant growth retardation.

![Identification of biallelic *LSS* mutations in patients with hypotrichosis; the *LSS* mutations of the patients were hypomorphic and led to decreased enzymatic activity *in vivo*, and analysis of skin pathology revealed acanthosis and hypoplastic hair follicles.\
**a**, Pedigree of the family. **b**, Photographs of patients II-2 and II-3. **c-f**, Histopathology of skin from patients II-2 and II-3. The epidermises exhibited psoriasiform acanthosis (arrow) and spongiosis (arrowhead). Scale bars = 600 μm (c, e), 60 μm (d, f). **g**, Immunoblot analysis of LSS expression in PBMCs from patients and controls. **h**, Overexpressed FLAG-LSS protein was detected with an anti-FLAG antibody. β-Actin was used as a loading control. Representative results from three independent experiments are shown. WT, wild type. **i, j**, LC-MS/MS analysis of (S)-2,3-epoxysqualene to lanosterol (i) and squalene to lanosterol (j) ratios in forehead sebum from the patients (n = 2), unaffected family members (n = 3), and controls (n = 37). P-values were calculated using Tukey-Kramer tests.](pgen.1008628.g001){#pgen.1008628.g001}

The second patient (patient II-3) was the third boy in the family ([Fig 1b](#pgen.1008628.g001){ref-type="fig"}). He was delivered at 32 weeks of gestation to FGR. His birth weight was 1,180 g (-2.86 SD), and height was 37.0 cm (-2.36 SD). As with the first patient, this patient exhibited treatment-resistant hypotrichosis and had a cleft palate and umbilical herniation. MR images of his head demonstrated a normal corpus callosum ([S3 Fig](#pgen.1008628.s003){ref-type="supplementary-material"}). At the most recent follow-up (16 years old), his height was 147.8 cm (-3.69 SD), and his body weight was 71.0 kg (1.09 SD), showing growth retardation similar to patient II-2.

Their motor and mental development of the patients are normal, and they do not present with cataracts. Histological analysis showed hypoplastic hair follicles, psoriasiform acanthosis, spongiosis, and hyperplastic sebaceous glands ([Fig 1c--1f](#pgen.1008628.g001){ref-type="fig"}). The hair follicles were hypoplastic, similar to what is observed with lanugo. Ultrastructural examination by transmission electron microscopy (TEM) revealed that the number of hair matrix cells or melanin granules was decreased, and that the inner root sheath was thin ([S4 Fig](#pgen.1008628.s004){ref-type="supplementary-material"}). The basement layer cells tightly adhered to each other, and the desmosomes developed normally.

*LSS* was identified as a single candidate gene by whole-exome sequencing {#sec004}
-------------------------------------------------------------------------

We performed family-based exome sequencing, for which we included the affected patients, an unaffected sibling and the unaffected parents. The mean depth of each exome was approximately 120. We identified only one candidate gene, *LSS* (NM_002340.5), for an autosomal recessive model in both patients ([S1 Table](#pgen.1008628.s016){ref-type="supplementary-material"}). No rare *de novo* variants or rare X-linked variants shared by the patients were identified. Sanger sequencing validated compound heterozygous mutations in *LSS*, namely, c.\[530G\>A\];\[701_716del\] (p.\[Arg177Gln\];\[Arg234Profs\*2\]), both of which were absent or extremely rare in ExAC, gnomAD, and the Human Genetic Variation Database (HGVD). The missense variant, p.Arg177Gln, was also predicted to be deleterious or pathogenic *in silico* (combined annotation-dependent depletion score, SIFT, Polyphen-2, and MutationTaster) ([S2 Table](#pgen.1008628.s017){ref-type="supplementary-material"}), and it affects evolutionarily conserved residues ([S5 Fig](#pgen.1008628.s005){ref-type="supplementary-material"}).

*In vitro* and *in vivo* assays revealed that the *LSS* mutations were hypomorphic and led to decreased enzymatic activity {#sec005}
--------------------------------------------------------------------------------------------------------------------------

An immunoblot analysis showed decreased expression of LSS protein in peripheral blood mononuclear cells (PBMCs) in the patients compared to the controls ([Fig 1g](#pgen.1008628.g001){ref-type="fig"}). The c.701_716del (p.Arg234Profs\*2) transcript was detected at a much lower level than the wild-type allele in the Epstein-Barr virus-transformed lymphoblastoid cell lines (EBV-LCLs) from the patients. Suppression of nonsense-mediated mRNA decay (NMD) by cycloheximide treatment increased the levels of the frameshifted transcript, indicating that the frameshifted allele resulted in an unstable transcript that was subjected to NMD ([S6 Fig](#pgen.1008628.s006){ref-type="supplementary-material"}). To test the stability of the mutant LSS proteins, we overexpressed wild-type or mutant FLAG-tagged LSS in HeLa cells. Exogenous expression of both LSS mutants was markedly reduced ([Fig 1h](#pgen.1008628.g001){ref-type="fig"}). The result of in vitro LSS expression suggested that the mutant protein stability was affected, although caution must be taken because overexpression studies sometimes do not reflect the protein stability of the mutants under physiological conditions. Next, we measured the levels of intermediate metabolites of cholesterol synthesis in human specimens to show LSS enzymatic inhibition *in vivo*. In plasma, we detected only (S)-2,3-epoxysqualene but not lanosterol by LC-MS/MS analysis ([S7 Fig](#pgen.1008628.s007){ref-type="supplementary-material"}). By contrast, in sebum from the skin, namely, the affected organ in the patients, we successfully detected squalene, (S)-2,3-epoxysqualene, and lanosterol by LC-MS/MS analysis. The ratios of (S)-2,3-epoxysqualene to lanosterol, that is, the ratios of the substrate to the product of LSS catalysis, in the sebum from the affected patients were significantly elevated compared to those of the unaffected family members and healthy volunteers ([Fig 1i](#pgen.1008628.g001){ref-type="fig"}). The ratios of the squalene to lanosterol were not different between the patients and the unaffected family members ([Fig 1j](#pgen.1008628.g001){ref-type="fig"}). Cholesterol could not be detected in the sebum of all of them, and the serum levels were not significantly different among the groups ([S3 Table](#pgen.1008628.s018){ref-type="supplementary-material"}).

*Lss* epidermis-specific knockout mice were neonatal lethal because of skin barrier dysfunction that led to severe dehydration {#sec006}
------------------------------------------------------------------------------------------------------------------------------

To confirm that loss-of-function of the cutaneous LSS protein causes hypotrichosis, we created epidermis-specific *Lss* knockout mice; *Lss* constitutive knockout mice were previously reported to be embryonic lethal, as mentioned above. *Lss flox/flox;Keratin14-Cre/+* (*Lss*^*f/f*^*-K14*) mice were obtained from breeding *Lss wild/flox;K14-Cre/+* male mice and *Lss flox/flox (Lss*^*f/f*^*)* female mice ([S8 Fig](#pgen.1008628.s008){ref-type="supplementary-material"}). The *Lss*^*f/f*^*-K14* mice did not have macroscopic whiskers ([Fig 2a](#pgen.1008628.g002){ref-type="fig"}). Genotype distribution of the *Lss*^*f/f*^*-K14* mice and the litters at 18.5 days post coitum were observed to conform to a Mendelian distribution (based on 51 litters, [S4 Table](#pgen.1008628.s019){ref-type="supplementary-material"}). Quantitative PCR (qPCR) analysis showed that *Lss* mRNA levels in the *Lss*^*f/f*^*-K14* mice were significantly lower than those in the *Lss*^*f/f*^ littermates in the epidermis but not significantly different in the liver ([Fig 2b](#pgen.1008628.g002){ref-type="fig"}). Lipid measurements showed that (S)-2,3-epoxysqualene was present in the skin epidermis of the *Lss*^*f/f*^*-K14* mice but not in the skin of the *Lss*^*f/f*^ littermates ([Fig 2c](#pgen.1008628.g002){ref-type="fig"}). Lanosterol and squalene were undetectable in the epidermis of both the *Lss*^*f/f*^*-K14* and *Lss*^*f/f*^ mice. Cholesterol was not significantly different between the epidermis of *Lss*^*f/f*^*-K14* and *Lss*^*f/f*^ mice ([S9 Fig](#pgen.1008628.s009){ref-type="supplementary-material"}).

![Epidermis-specific *Lss* knockout neonatal mice exhibited no vibrissae and died of severe dehydration due to skin barrier dysfunction.\
**a**, Facial appearance of a neonatal *Lss*^*f/f*^ or *Lss*^*f/f*^*-K14* mouse. The magnified images show the presence of whiskers in an *Lss*^*f/f*^ mouse but not in an *Lss*^*f/f*^*-K14* mouse. **b**, Quantitative PCR analysis of *Lss* in the epidermis (left) and liver (right) of newborn *Lss*^*f/f*^*-K14* or *Lss*^*f/f*^ mice. Relative amounts of mRNA were determined using the comparative Ct method. Each bar represents the mean ± SEM (n = 6 per group). P-values were calculated using Student's *t*-tests. NS, not significant. **c**, Lipid analysis of newborn *Lss*^*f/f*^*-K14* (n = 7) or *Lss*^*f/f*^ (n = 8) skin for (S)-2,3-epoxysqualene. All bars represent the means. P-values were calculated using Student's *t*-tests. **d**, Percent body weight based on the birth weights over time. The body weight loss of *Lss*^*f/f*^ -K14 mice (n = 5), which was over 10% until 6 hours after birth, was significantly higher than the loss observed in *Lss*^*f/f*^ (n = 11) or *Lss*^*wild/f*^*-K14* (n = 9) mice. No significant reduction in weight loss between *Lss*^*f/f*^ (n = 11) and *Lss*^*wild/f*^*-K14* (n = 9) mice was observed. Each bar represents the mean ± SD. \*P \< 0.0001, P-values were calculated using Student's *t*-tests. **e**, Dye penetration assay on a newborn *Lss*^*f/f*^*-K14* or *Lss*^*f/f*^ mouse. The experiments were repeated three times. **f**, Measurement of TEWL in newborn *Lss*^*f/f*^*-K14* (n = 5) or *Lss*^*f/f*^ (n = 7) mice. P-values were calculated using Student's *t*-tests. **g**, TEM of the epidermis of newborn *Lss*^*f/f*^*-K14* or *Lss*^*f/f*^ mice. Desmosomes were hypoplastic in the *Lss*^*f/f*^*-K14* mice compared to those observed in *Lss*^*f/f*^ littermates. Scale bars = 100 nm. Data are from at least two independent experiments. P-values were calculated using Student's *t*-tests.](pgen.1008628.g002){#pgen.1008628.g002}

Their hair growth could not be investigated because all of the *Lss*^*f/f*^*-K14* mice died within a few hours after birth. The body weight loss exhibited by these mice was significantly greater than that of *Lss*^*wild/f*^*-K14* and *Lss*^*f/f*^ mice, and it was greater than 10% until 6 hours after birth ([Fig 2d](#pgen.1008628.g002){ref-type="fig"}); thus, severe dehydration immediately after birth was suspected as the cause of death. A dye penetration assay using toluidine blue showed that the *Lss*^*f/f*^*-K14* mice exhibited higher levels of staining than the *Lss*^*f/f*^ littermates ([Fig 2e](#pgen.1008628.g002){ref-type="fig"}), which indicated outside-in skin barrier dysfunction in the *Lss*^*f/f*^*-K14* mice. Transepidermal water loss (TEWL) was significantly higher in the *Lss*^*f/f*^*-K14* mice than it was in the *Lss*^*f/f*^ littermates, which indicated inside-out skin barrier impairment in the *Lss*^*f/f*^*-K14* mice ([Fig 2f](#pgen.1008628.g002){ref-type="fig"}). A light microscopic study did not show apparent differences between the *Lss*^*f/f*^*-K14* and *Lss*^*f/f*^ mice ([S10a Fig](#pgen.1008628.s010){ref-type="supplementary-material"}). Expression of the LSS protein was decreased in the epidermal basement membrane of the *Lss*^*f/f*^*-K14* mice compared to what was observed in the *Lss*^*f/f*^ littermates by immunohistochemistry ([S10b Fig](#pgen.1008628.s010){ref-type="supplementary-material"}). The number of follicles and the thickness of the epidermis were not significantly different between the *Lss*^*/f*^*-K14* and *Lss*^*f/f*^ mice. TEM revealed hypomorphic changes in the desmosomes of the *Lss*^*f/f*^*-K14* mice ([Fig 2g](#pgen.1008628.g002){ref-type="fig"}).

Epidermal *Lss* ablation led to transient epilation in tamoxifen-inducible knockout mice {#sec007}
----------------------------------------------------------------------------------------

Next, we utilized a tamoxifen-inducible Cre/loxP system and generated *Lss flox/flox;Keratin14-Cre-ERT/+* (*Lss*^*f/f*^*-K14ERT*) mice to avoid neonatal death. Epilation in the *Lss*^*f/f*^*-K14ERT* mice occurred over 3 weeks after intraperitoneal injections of tamoxifen. In the following 1 to 2 weeks, the hair loss area peaked ([Fig 3a and 3b](#pgen.1008628.g003){ref-type="fig"}). The fur gradually regrew, but it was not completely restored and remained sparse ([Fig 3b](#pgen.1008628.g003){ref-type="fig"}). The surfaces of the ears or tails were reddish and rough ([Fig 3b](#pgen.1008628.g003){ref-type="fig"}). Tamoxifen-treated *Lss*^*f/f*^ or untreated *Lss*^*f/f*^*-K14ERT* mice did not exhibit any phenotype ([Fig 3a](#pgen.1008628.g003){ref-type="fig"}). The ratios of (S)-2,3-epoxysqualene to lanosterol were significantly higher in the sebum of tamoxifen-treated *Lss*^*f/f*^*-K14ERT* mice compared to the ratios in the tamoxifen-treated *Lss*^*f/f*^ or untreated *Lss*^*f/f*^*-K14ERT* mice ([Fig 3c](#pgen.1008628.g003){ref-type="fig"}). Histological analysis of the *Lss*^*f/f*^*-K14ERT* mice revealed hypoplastic hair follicles, hyperplastic sebaceous glands, and thin root sheaths, which was consistent with the pathological results obtained from the patients ([Fig 3d](#pgen.1008628.g003){ref-type="fig"}). The epidermises exhibited hyperplasia, parakeratosis, hyperkeratosis and liquefaction degeneration. Immunohistochemical analysis showed that the LSS protein levels decreased in the sebaceous gland and epidermal basal layer cells after tamoxifen treatment ([Fig 3e](#pgen.1008628.g003){ref-type="fig"}). In contrast, the keratinocytes in the surface layer exhibited positive immunostaining for LSS. As the proportion of immunostained cells in the sebaceous glands decreased, the proliferation of the nearby epidermal cells increased ([S11 Fig](#pgen.1008628.s011){ref-type="supplementary-material"}).

![Inducible epidermis-specific deletion of *Lss* caused alopecia that was spontaneously and partially reversed in the mice.\
**a**, Gross appearance of the *Lss*^*f/f*^*-K14ERT* or *Lss*^*f/f*^ mice pre- and postadministration of intraperitoneal tamoxifen. *Lss*^*f/f*^*-K14ERT* mice 4 weeks after tamoxifen treatment, which affected baldness from the head to the back. The experiments were repeated at least three times. **b**, The peak of hair loss in *Lss*^*f/f*^*-K14ERT* mice was 5 weeks after the tamoxifen treatment (top). The hair had spontaneously regrown 7 weeks after the treatment (bottom). W, weeks. **c**, Skin sebum analysis of *Lss*^*f/f*^*-K14ERT* (n = 15) or *Lss*^*f/f*^ (n = 13) mice pre- and postadministration of intraperitoneal tamoxifen or vehicle. At 6 weeks of age, (S)-2,3-epoxysqualene was not detected in either *Lss*^*f/f*^*-K14ERT* (n = 3) or *Lss*^*f/f*^ (n = 3) mice. After 4 weeks of treatment, the ratios of (S)-2,3-epoxysqualene to lanosterol in the sebum of tamoxifen-treated *Lss*^*f/f*^*-K14ERT* mice (n = 6) were significantly elevated compared to those of vehicle-treated *Lss*^*f/f*^ (n = 4), tamoxifen-treated *Lss*^*f/f*^ (n = 6), or vehicle-treated *Lss*^*f/f*^*-K14ERT* (n = 6) mice. P-values were calculated using Tukey-Kramer tests. NS, not significant. **d**, H&E staining and **e**, LSS immunohistochemistry of skin from *Lss*^*f/f*^*-K14ERT* or *Lss*^*f/f*^ mice 4 weeks after tamoxifen treatment. The epidermis of *Lss*^*f/f*^*-K14ERT* mice showed severe acanthosis compared to *Lss*^*f/f*^ mice. LSS protein expression was decreased in the epidermal basement membrane (open arrowhead) and sebaceous cells (closed arrowhead) of the *Lss*^*f/f*^*-K14* mice compared to the expression in *Lss*^*f/f*^ mice. Scale bars = 100 nm.](pgen.1008628.g003){#pgen.1008628.g003}

In addition, we topically administered 4-hydroxytamoxifen, which is an activated form of tamoxifen *in vivo*, on the skin of *Lss*^*f/f*^*-K14ERT* mice or littermates. Consistent with the results of the intraperitoneal injections with tamoxifen, the 4-hydroxytamoxifen-treated areas exhibited transient epilation in *Lss*^*f/f*^*-K14ERT* mice ([S12 Fig](#pgen.1008628.s012){ref-type="supplementary-material"}). *Lss*^*f/f*^ (n = 2) and *Lss*^*wild/f*^*-K14ERT* (n = 2) mice, which were the littermates of the treated *Lss*^*f/f*^*-K14ERT* mice, did not show hair loss following topical administrations of 4-hydroxytamoxifen.

Lens-specific *Lss* knockout mice had congenital cataracts {#sec008}
----------------------------------------------------------

We created *Lss flox/flox;Pax6-Cre/+* (*Lss*^*f/f*^*-Pax6*) mice in which the *Pax6* promoter was selected to create lens-specific knockout model mice \[[@pgen.1008628.ref011],[@pgen.1008628.ref012]\]. The *Lss*^*f/f*^*-Pax6* mice exhibited microphthalmia and small cloudy lenses that were not observed in the controls ([Fig 4a--4d](#pgen.1008628.g004){ref-type="fig"}). Pathological analysis of the *Lss*^*f/f*^*-Pax6* mice indicated lens swelling, degeneration, and liquefaction ([Fig 4e--4h](#pgen.1008628.g004){ref-type="fig"}), which implied cataract changes. Immunohistochemical analysis demonstrated that the LSS protein levels were lower in the *Lss*^*f/f*^*-Pax6* mice than they were in the *Lss*^*f/f*^ mice ([Fig 4i--4l](#pgen.1008628.g004){ref-type="fig"}). The inner retina, which is the inner nuclear layer and ganglion cell layer, was thinner in *Lss*^*f/f*^*-Pax6* mice than it was in *Lss*^*f/f*^ mice ([S13 Fig](#pgen.1008628.s013){ref-type="supplementary-material"}). In particular, there were fewer retinal ganglion cells in *Lss*^*f/f*^*-Pax6* mice than there were in *Lss*^*f/f*^ mice. (S)-2,3-epoxysqualene, lanosterol, squalene, and cholesterol were not detected in the lenses of *Lss*^*f/f*^ or *Lss*^*f/f*^*-Pax6* mice.

![Lens-specific deletion of *Lss* caused cataracts in mice.\
**a-d**, Images of *Lss*^*f/f*^*-PAX6* or *Lss*^*f/f*^ mice (14 weeks of age) and their lenses. **e-l**, H&E staining and immunohistochemistry of the lenses of *Lss*^*f/f*^*-PAX6* or *Lss*^*f/f*^ mice. These experiments were repeated at least three times. Scale bars = 500 μm (b), 50 μm (c).](pgen.1008628.g004){#pgen.1008628.g004}

Discussion {#sec009}
==========

Here, we describe two sibling patients with biallelic *LSS* loss-of-function mutations that led to compromised LSS protein expression and an increased ratio of substrate to product in the patients' sebum, indicating LSS enzymatic inhibition *in vivo*. The LSS enzyme disruption was also reproducible in the skin sebum of inducible epidermis-specific *Lss* knockout mice. Previous studies could not demonstrate LSS dysfunction by analysis of blood samples \[[@pgen.1008628.ref007],[@pgen.1008628.ref008]\]. Measurement of cholesterol intermediates from skin, an affected organ, but not blood, allowed us to validate the LSS enzymatic block. The ratio of (S)-2,3-epoxysqualene to lanosterol in the sebum would be a good biomarker for the diagnosis of LSS deficiency. Hypotrichosis and cataracts were reproduced by creating tissue-specific *Lss* knockout mice. Our results confirmed that hypotrichosis and cataracts, the core symptoms in patients with biallelic *LSS* mutations, are caused by LSS enzymatic deficiency in each tissue, not by circulating abnormal metabolites in the blood.

We recapitulated hypotrichosis and cataracts by creating tissue-specific *Lss* knockout mice, and these outcomes are caused by knocking out *Lss* in the respective organs. Both of these symptoms are also associated with other inherited disorders of cholesterol biosynthesis. Hypotrichosis is observed in other conditions associated with deficiencies of cholesterol synthesis enzymes, including Greenberg dysplasia, SC4MOL deficiency, X-linked dominant chondrodysplasia punctata-2 (CDPX2), and congenital hemidysplasia with ichthyosiform erythroderma and limb defects (CHILD) syndrome \[[@pgen.1008628.ref013]--[@pgen.1008628.ref017]\]. Cataracts are also known to develop in patients with deficiencies of cholesterol synthesis enzymes, such as SC4MOL deficiency, CDPX2, lathosterolosis and Smith-Lemli-Opitz syndrome (SLOS) \[[@pgen.1008628.ref016],[@pgen.1008628.ref018]--[@pgen.1008628.ref020]\]. However, given that most mice that have had cholesterol synthesis genes knocked out are embryonic lethal \[[@pgen.1008628.ref021]\], conventional knockout mouse studies are not feasible for recapitulation of the symptoms in patients with these deficiencies. Moreover, it is not understood whether symptoms of patients with abnormal cholesterol metabolism are local events or are secondary effects caused by enzyme deficits. Our study validated that local abnormalities in cholesterol metabolism can cause symptoms in each tissue using conditional knockout mouse models; the results are similar to those from a previous mouse study of Insig-1/2, which is involved in a feedback system of cholesterol synthesis \[[@pgen.1008628.ref022]\].

Tamoxifen-induced *Lss* knockout in the mouse epidermis led to epilation. The hyperkeratosis observed in the epidermis was consistent with the ichthyosis observed in the patient during the neonatal period ([S2 Fig](#pgen.1008628.s002){ref-type="supplementary-material"}) and with the histological analysis of the patient's skin ([Fig 1c and 1d](#pgen.1008628.g001){ref-type="fig"}). Recent studies also demonstrated similar dermatological findings, including ichthyosis, in other patients with biallelic *LSS* mutations \[[@pgen.1008628.ref008]\]. As with hypotrichosis, hyperkeratosis also occurs in other disorders of cholesterol biosynthesis \[[@pgen.1008628.ref013]--[@pgen.1008628.ref017]\]. Interestingly, the epilation of the tamoxifen-treated mice was transient. A possible explanation for the hair regrowth is that the surrounding cells might supply LSS-deficient cells with deficient products or consume excess substrates. Consistent with this hypothesis, a severe phenotype was observed in parts of the body with few subcutaneous tissues, such as the ears ([Fig 3b](#pgen.1008628.g003){ref-type="fig"}) and tail. Contrary to the tamoxifen-inducible system, the phenotypes of LSS deficiency were not fully reproduced in the *Lss*^*f/f*^*-K14* mice due to neonatal lethality. The mice failed to develop normal skin, which especially affected the skin barrier function. The failure to develop a skin barrier is consistent with the mouse knockout of *DHCR24*, which catalyzes cholesterol intermediates \[[@pgen.1008628.ref023]\]. Of note, in our experiments, only one mouse grew to the adult stage ([S14 Fig](#pgen.1008628.s014){ref-type="supplementary-material"}). The mouse grew normally and could not be differentiated from the other littermates until weaning but gradually exhibited baldness and affected skin scales after approximately 6 weeks of age. Unlike the tamoxifen-treated *Lss*^*f/f*^*-K14ERT* mice, alopecia was not recovered in this mouse until the mouse died of unknown causes at 10 weeks of age. Considering that the hair follicles of epidermis-specific knockout mice developed normally ([S11 Fig](#pgen.1008628.s011){ref-type="supplementary-material"}), cell-autonomous cholesterol biosynthesis by LSS enzyme might be crucial not for morphogenesis and primary hair development but for secondary hair germ in hair development. By preventing water evaporation from the skin, *Lss*^*f/f*^*-K14* mice might avoid neonatal lethality. If the *Lss*^*f/f*^*-K14* mice could survive and reach adulthood, these mice would be excellent animal models for clarifying the pathophysiology related to disrupted *Lss* and investigating treatments.

The pathogenesis of LSS deficiency is unknown, but the mechanism is likely attributed to aberrant SHH or WNT signaling. Although the association of *LSS* mutations and holoprosencephaly was not proven by pedigree analysis in a previous study \[[@pgen.1008628.ref024]\], some patients with *LSS* mutations, including our patients, have midline anomalies or growth failure \[[@pgen.1008628.ref008]\], which are observed in diseases of cholesterol metabolism or SHH signaling \[[@pgen.1008628.ref025],[@pgen.1008628.ref026]\]. SLOS, which impairs cholesterol synthesis due to DHCR7 deficiency and often produces similar symptoms, has been proposed to be involved in the SHH pathway \[[@pgen.1008628.ref020],[@pgen.1008628.ref027]\]. WNT signaling, which interacts with SHH-related molecules during embryogenesis in several tissues, is also required for hair follicle generation \[[@pgen.1008628.ref028]\]. Thus, we surveyed whether LSS deficiency caused Shh or Wnt dysregulation. However, there were no significant differences in Shh or Wnt transcriptional responses against the exogenous Shh or Wnt protein between *Lss*-depleted and nondepleted MEFs ([S15 Fig](#pgen.1008628.s015){ref-type="supplementary-material"}). These results might imply that the underlying mechanism is not simply caused by the upregulation or downregulation of these signaling pathways because spatial and gradient SHH or WNT signaling seems to be key in skin formation \[[@pgen.1008628.ref029]\]. Moreover, the reason why each patient with biallelic *LSS* mutations shows different combinations of phenotypes, such as hypotrichosis and/or cataracts, is also unknown \[[@pgen.1008628.ref005]--[@pgen.1008628.ref008]\]. Further experimental studies are required to understand the pathogenesis and mechanism of the phenotypic variation in LSS deficiency.

In conclusion, our study verified that biallelic *LSS* mutations caused LSS enzymatic dysfunction in skin through analysis of sebum. Our mouse studies underscored that hypotrichosis and cataracts are caused by LSS enzymatic dysfunctions in each tissue. Local treatment in LSS deficiency might alleviate symptoms; patients with CHILD syndrome, a deficiency of downstream intermediates of LSS, was successfully treated by topical application of statin or cholesterol plus statin \[[@pgen.1008628.ref015],[@pgen.1008628.ref030]\]. The mouse model of LSS deficiency might serve as a pathophysiological research model and aid in the development of novel treatments.

Materials and methods {#sec010}
=====================

Sequencing analysis {#sec011}
-------------------

Whole-exome sequencing was performed as described elsewhere \[[@pgen.1008628.ref031]\] but with minor modifications. Briefly, genomic DNA was purified using a SureSelectXT Human All Exon V5 (50 Mb) Kit (Agilent Technologies, Santa Clara, CA, USA) and was sequenced on a HiSeq2000 (Illumina, San Diego, CA, USA) with 101-base-pair paired-end reads. The reads were mapped to the human genome build UCSC hg19 using Novoalign v. 2.08.05 (<http://www.novocraft.com>), and single-nucleotide variants (SNVs) and insertions and/or deletions (indels) were identified using the Genome Analysis Toolkit (GATK) v. 1.6--13. After quality filtering, variants were annotated using ANNOVAR. Nonsynonymous SNVs, splice-site variants and indels were retained. We excluded variants present at \<1% minor allele frequency (MAF) in the 1000 Genomes database, the ExAC database version 0.3 (all and East Asian populations) and the HGVD. Sanger sequencing was performed to validate the variants identified by whole-exome sequencing.

Plasmids {#sec012}
--------

Wild-type, R234fs, and R177Q human *LSS* cDNAs (NM_002340.5, carrying SNP rs2254422 and rs2254524) were prepared by RT-PCR with RNA from the blood of the patients and their family members. cDNAs were subcloned into pCMV6-AN-DDK (PS100014, OriGene, Rockville, MD, USA). The final constructs were verified by sequencing.

Cell culture and transfection {#sec013}
-----------------------------

HeLa cells (RCB0007, provided by the RIKEN BRC through the National BioResource Project of the MEXT, Japan) were cultured in Dulbecco's modified Eagle's medium (DMEM) containing low levels of glucose, which was supplemented with 10% fetal bovine serum and 1% penicillin and streptomycin (100 U/ml and 100 μg/ml, respectively); cells were maintained at 37°C in a 5% CO~2~ incubator. The pCMV6-FLAG-LSS (wild-type, R234fs, and R177Q) plasmid was transfected into HeLa cells using Lipofectamine LTX (15338100, Thermo Fisher Scientific Inc., MA, USA). Twenty-four hours after transfection, cell lysates were harvested and subjected to immunoblot analysis.

Western blot analysis {#sec014}
---------------------

Proteins extracted from PBMCs or HeLa cells expressing FLAG-LSS were subjected to immunoblot analysis. Mouse anti-FLAG (F3165, Sigma-Aldrich, Merck Millipore), rabbit anti-LSS (13715-1-AP, Proteintech, Rosemont, IL, USA), HRP-conjugated anti-mouse IgG (NA9310V, GE Healthcare UK Ltd., Buckinghamshire, England), HRP-conjugated anti-rabbit IgG (NA9340V, GE Healthcare UK Ltd.), and peroxidase-conjugated anti-β-actin (017--24573, Wako, Osaka, Japan) antibodies were used.

Sample collection and preparation for LC-MS/MS analysis {#sec015}
-------------------------------------------------------

Human sebum was collected using acetone-soaked cotton pads as described previously \[[@pgen.1008628.ref032]\], and it was extracted with acetone. Mouse sebum was collected similarly and was syringe filtered (GL Chromatodisc 25N, GL Sciences, Tokyo, Japan). Mouse skin was sampled as described previously \[[@pgen.1008628.ref033]\]. Mouse skin homogenates were prepared using 0.9% KCl containing 1 mM ethylenediaminetetraacetic acid. Total lipids from the above samples and human serum were extracted by the Folch method as described previously \[[@pgen.1008628.ref034],[@pgen.1008628.ref035]\] but with modifications. All samples were dissolved in methyl *tert*-butyl ether (MTBE)/methanol (2:1) prior to analysis.

LC-MS/MS analysis {#sec016}
-----------------

Samples were analyzed with a QTRAP 4000 mass spectrometer equipped with an Exion HPLC system (SCIEX, Tokyo, Japan). Samples were eluted from a C30 column (YMC Carotenoid 250×4.6 mm, YMC, Kyoto, Japan) at a flow rate of 1.0 mL/min with a binary gradient consisting of solvent A (methanol/MTBE/water, 83:15:2) and solvent B (methanol/MTBE/water, 8:90:2). The gradient profile was as follows: 0--10 min, 0--50% B, linear; 10--20 min, 100% B; 20--25 min, 0% B. The column temperature was maintained at 40°C. Compounds were detected with atmospheric-pressure chemical ionization in positive ion mode, and they were identified through comparison of peaks between the samples and commercial standards. Compounds were quantified with external calibration curves using the corresponding standards. Further MS conditions are described in [S5 Table](#pgen.1008628.s020){ref-type="supplementary-material"}.

Mice {#sec017}
----

Cryopreserved sperm of *Lss* tm1a knockout mice were purchased from the European Mouse Mutant Archive. Heterozygous *Lss* tm1a mice were generated at the Institute for Animal Experimentation, Tohoku University Graduate School of Medicine, and then they were crossed with *Flpe* mice (RBRC01834, RIKEN BRC, Japan) \[[@pgen.1008628.ref036]\] to obtain *Lss wild/flox* mice that had a conditional allele ([S8 Fig](#pgen.1008628.s008){ref-type="supplementary-material"}). *Lss wild/flox* mice were bred with *K14-Cre* transgenic mice (stock no. 004782; The Jackson Laboratory, USA) to generate epidermis-specific knockout mice. *Lss*^*f/f*^*-K14ERT* or *Lss*^*f/f*^*-Pax6* mice were similarly created using *K14-CreERT* transgenic mice (stock no. 005107; The Jackson Laboratory, USA) or *PAX6-Cre* transgenic mice (stock no. 024688; The Jackson Laboratory, USA), respectively. All mice in these studies were on a C57BL/6 background except the *K14-CreERT* mice, which were a strain of ICR mice backcrossed with C57BL/6 mice for at least 5 generations. Day 0.5 of pregnancy (E0.5) was defined as the morning on the day after overnight mating. Mouse tail genomic DNA was extracted with a Maxwell 16 Mouse Tail DNA Purification Kit (Promega, USA). Mouse genotypes were determined by probe-based PCR analysis. The PCR primers (Nihon Gene Research Laboratories, Miyagi, Japan) and probes (Integrated DNA Technologies, Coralville, IA, USA) are described in [S6 Table](#pgen.1008628.s021){ref-type="supplementary-material"}. Tamoxifen (T5648, Sigma-Aldrich, USA) was dissolved in corn oil, and 1 mg was injected intraperitoneally daily for 5 consecutive days. 4-Hydroxytamoxifen (H954725, Toronto Research Chemicals, Toronto, Canada) was dissolved in 100% acetone at 4 mg/dl, and 0.4 mg was topically applied daily for 5 consecutive days.

qPCR analysis {#sec018}
-------------

The mouse epidermises were isolated after allowing the skin to float on trypsin for 24 hours. Epidermis and liver were homogenized using a pellet pestle cordless motor (Kimble, Vineland, NJ, USA). RNA was extracted with RNeasy (QIAGEN, Hilden, Germany), and reverse transcription was performed with a PrimeScript RT Reagent Kit with gDNA Eraser (TakaraBio, Shiga, Japan). cDNA was amplified with TaKaRa Ex Taq (RR001A, TaKaRa Bio Inc., Otsu, Japan) and PrimeTime qPCR probe assays (Integrated DNA Technologies, Coralville, IA, USA). qPCR primers and probes for *Lss* (Mm.PT.58.41802559) and *Gapdh* (Mm.PT.39a.1) were used. qPCR reactions were performed using StepOnePlus (Sigma-Aldrich, St. Louis, MO, USA) with standard conditions.

Histology and immunohistochemistry {#sec019}
----------------------------------

Skin samples were fixed in formalin, embedded, and cut into 5-μm sections. HE staining was performed using standard procedures. For immunostaining, slides were incubated with an anti-LSS antibody according to the manufacturer's instructions (13715-1-AP, Proteintech, Rosemont, IL, USA). Images were captured with a BIOREVO BZ-9000 microscope (Keyence, Osaka, Japan).

Electron microscopy {#sec020}
-------------------

Mouse skin samples were fixed with 2% paraformaldehyde and 2.5% glutaraldehyde in 0.1 M cacodylate buffer overnight at 4°C. After being cut into small pieces, the specimen was postfixed in 1% osmium tetroxide for 90 min on ice, rinsed in distilled water, successively dehydrated in 50, 60, 70, 80, 90, and 95% ethanol for 10 min each (except for 70% ethanol, which was used for 25 min). Then, specimens were incubated in for 20 minutes 100% ethanol (3 times), treated with propylene oxide for 10 min (2 times), and finally, embedded in epoxy resin. Ultrathin (80 nm) sections were prepared on an ultramicrotome (EM UC-7, Leica, Heerbrugg, Switzerland) with a diamond knife, and then slides were stained with 2% uranyl acetate and 1% lead citrate and were viewed using an electron microscope (H-7600, Hitachi, Tokyo, Japan).

Skin barrier function assays {#sec021}
----------------------------

A dye penetration assay was performed as described previously \[[@pgen.1008628.ref037]\]. Briefly, newborn mice were rinsed in PBS and successively dehydrated in 25, 50, 75, and 100% methanol for 1 min each. Mice were then rehydrated with PBS, stained with 0.05% toluidine blue in PBS for 10 min, destained with PBS for 20 min, and photographed. All steps were performed at room temperature. TEWL was recorded using AquaFlux (Biox, London, UK). Measurements were performed after calibrating the device at room temperature.

Statistical analysis {#sec022}
--------------------

Statistical analysis was performed with JMP Pro 13.0. P-values \<0.05 were considered statistically significant.

Ethics statement {#sec023}
----------------

Approval for human subject research was obtained from the ethics committee of Tohoku University Graduate School of Medicine (approval number: 2015-1-694). Written informed consent was obtained from all participants in the study. Approval for animal experiments was provided by the Animal Care Facility of the Tohoku University Graduate School of Medicine (approval number: 2016MdA-371, 2016MdA-372).

Supporting information {#sec024}
======================

###### The metabolic pathway of cholesterol biosynthesis.

Cholesterol is synthesized from acetyl CoA via the Bloch or Kandutsch-Russell pathway. In this synthesis pathway, LSS converts (S)-2,3-epoxysqualene to lanosterol. The abbreviations are as follows: FDFT1, farnesyldiphosphate farnesyltransferase 1; ff-MAS, follicular fluid meiosis-activating sterol; t-MAS, testis-meiosis activating sterol; LBR, lamin B receptor; SC4MOL, sterol C4-methyloxidase-like; NSDHL, NAD(P)H steroid dehydrogenase-like protein; HSD17B7, 17-beta-hydroxysteroid dehydrogenase; EBP, emopamil-binding protein; SC5DL, sterol C5-desaturase; DHCR7, 7-dehydrocholesterol reductase; and DHCR24, 24-dehydrocholesterol reductase.

(TIF)

###### 

Click here for additional data file.

###### Patient II-2 at 1 month of age.

The patient exhibited ichthyosis-like scales on the skin of his chest, abdomen and upper extremities but not on his face and head.

(TIF)

###### 

Click here for additional data file.

###### Sagittal T1-weighted head MRI images of patients II-2 and II-3.

Sagittal T1-weighted head MRI shows partial agenesis of the corpus callosum (from the posterior midbody to splenium) in patient II-2, while the MRI shows a normal corpus callosum in patient II-3.

(TIF)

###### 

Click here for additional data file.

###### Transmission electron microscopy images of the skin of patient II-3.

\(a\) Hair matrix of the patient. The number of melanin granules was small. The inner root sheath was thin. (b) The basement layer cells were tightly adhered to each other. (c) The desmosome was well developed. Scale bars = 200 μm (a), 50 μm (b), and 2.5 μm (c).

(TIF)

###### 

Click here for additional data file.

###### Conservation of a missense variant in LSS.

The R177Q residue is conserved in organisms from humans to zebrafish. LSS homologs were aligned with Clustal Omega.

(TIF)

###### 

Click here for additional data file.

###### The frameshift variant c.701_716del in *LSS* leads to NMD.

EBV-LCLs from patient II-2 and II-3 were treated with 100 μg/mL cycloheximide (037--20991, FUJIFILM Wako Pure Chemical Corporation, Osaka, Japan) for 4 hours to suppress NMD. Total RNA was extracted with an RNeasy Kit (Qiagen Inc., Valencia, CA, USA). RT-PCR was performed using a PrimeScript^™^ II High Fidelity RT-PCR Kit (TaKaRa, Shiga, Japan) to amplify the cDNA surrounding the c.701_716del mutation, which was followed by Sanger sequencing.

(TIF)

###### 

Click here for additional data file.

###### Mass spectra was collected by LC-MS/MS for the plasma from the patients or family members.

Blue arrows indicate peaks of 2,3-oxidosqualene. Lanosterol could not be detected by this analysis.

(TIF)

###### 

Click here for additional data file.

###### Diagrams of the knockout allele.

The tm1a allele was a knockout first allele, and it was converted to a conditional allele, tm1c (flox), by FLP-mediated recombination. The tm1c (flox) allele was converted to a deletion allele by Cre-mediated recombination.

(TIF)

###### 

Click here for additional data file.

###### Cholesterol quantification in newborn *Lss*^*f/f*^*-K14* or *Lss*^*f/f*^ skin.

Mouse skin was gravimetrically weighed, and homogenates were prepared using 0.9% KCl containing 1 mM ethylenediaminetetraacetic acid. Total lipids were extracted from the homogenates using the Folch method \[[@pgen.1008628.ref034], [@pgen.1008628.ref035]\], and the extract was dissolved in 100 μL of 2-propanol. Human sebum was collected using acetone-soaked cotton pads \[[@pgen.1008628.ref032]\], and it was dissolved in 200 μL of 2-propanol. The total cholesterol content in each sample was measured enzymatically with a commercial kit (Cholesterol E; Wako Pure Chemical Industries, Ltd., Osaka, Japan) according to the manufacturer's protocol. Each bar represents the mean ± SEM (n = 5 per group). P-values were calculated using Student's *t*-tests. NS, not significant.

(TIF)

###### 

Click here for additional data file.

###### Light microscopic images of *Lss*^*f/f*^*-K14* and *Lss*^*f/f*^ mouse skin.

\(a\) Histological analysis did not show macroscopic differences in epidermal structure between the *Lss*^*f/f*^*-K14* and *Lss*^*f/f*^ mice. (b) Immunohistochemistry showed that expression of the LSS protein was decreased in the epidermal basement membrane (open arrowhead) and hair follicles (closed arrowhead) of the *Lss*^*f/f*^*-K14* mice compared to the *Lss*^*f/f*^ littermates. Scale bars = 100 μm.

(TIF)

###### 

Click here for additional data file.

###### Immunohistochemical analysis of skin from *Lss*^*f/f*^*-K14ERT* mice with alopecia.

Keratosis is mild in epidermal areas near immunostained sebaceous cells (a, b). In contrast, severe keratosis is found in epidermal areas lacking immunostained sebaceous cells (c). Scale bars = 100 μm.

(TIF)

###### 

Click here for additional data file.

###### Topical tamoxifen-treated *Lss*^*f/f*^*-K14ERT* mice.

Images of *Lss*^*f/f*^*-K14ERT* mice arranged chronologically after topical application of 4-hydroxytamoxifen, which was applied within the black rectangle. Depilation gradually occurred after 3 weeks of 4-hydroxytamoxifen treatment. The depilation area was greatest after 4 weeks. Similar to the effects of intraperitoneal injection of tamoxifen, the hair gradually regrew. Gray hairs were mixed among the hairs in the recovered area.

(TIF)

###### 

Click here for additional data file.

###### Microscopic analysis of the retina in *Lss*^*f/f*^*-Pax6 and Lss*^*f/f*^ mice.

The inner retina, which is the inner nuclear layer and ganglion cell layer, was thin in *Lss*^*f/f*^*-Pax6* mice compared to *Lss*^*f/f*^ mice. There were fewer retinal ganglion cells in *Lss*^*f/f*^*-Pax6* mice than there were in *Lss*^*f/f*^ mice. In contrast, there was no obvious difference in the thickness of the outer nuclear layers between *Lss*^*f/f*^*-Pax6* and *Lss*^*f/f*^ mice. These pictures were captured using an Olympus BX53 microscope (Olympus, Tokyo, Japan). A 10x objective lens was used. Scale bars = 50 μm.

(TIF)

###### 

Click here for additional data file.

###### The surviving *Lss*^*f/f*^*-K14* mouse.

Sequential images of an adult *Lss*^*f/f*^*-K14* mouse (a-d). At weaning, the mouse could not be differentiated from the other littermates. The mouse gradually lost hair after 6 weeks of age (a). Desquamation started at 9 weeks of age (c). A partial skin defect on the head with oozing was observed. The mouse died due to unknown causes at 10 weeks of age (d). Analysis of histological specimens from the dead mouse revealed severe hyperkeratosis, dyskeratosis, and hypertrophic sebaceous cells (e). Scale bars = 100 μm.

(TIF)

###### 

Click here for additional data file.

###### Transcriptional responses against the exogenous Shh or Wnt protein between *Lss*-depleted and nondepleted MEFs.

We measured the transcriptional responses of MEFs against the exogenous Shh or Wnt protein as previously described \[[@pgen.1008628.ref027], [@pgen.1008628.ref038]\] with minor modifications. Embryos (E13.5--14.5) were harvested by aseptic techniques from pregnant *Lss*^*f/f*^ mice that had been mated with *Lss*^*f/f*^ male mice. The heads, extremities, and tails were cut off, and the livers were removed. The remaining body parts were minced by scissors and transferred to a 50 mL tube with PBS. The tube was centrifuged at 200 g for 5 min. The supernatant was aspirated, and the pellet was resuspended with 1 mL 0.25% trypsin-EDTA per embryo. The suspension was incubated for 15 min in a 37°C water bath with shaking. Fetal bovine serum was added (the same volume as trypsin) to the suspension. After letting the suspension sit for several minutes and allowing the embryo fragments sank to the bottom of the tube, the serous part was removed first and filtered, and then the remaining thick part was passed through a 100 μm filter. The filtered solution was centrifuged at 200 g for 5 min. The supernatant was aspirated, the pellet was resuspended in DMEM, and the suspension was transferred to a dish. MEFs were plated at 5 × 10^4^ cells in 250 μL of DMEM per 48-well plate and transduced with AAV1 or a mock control (105548-AAV1 or 105537-AAV1, respectively, Addgene, Cambridge, MA, USA) at a multiplicity of infection of 5 ×10^5^. The next day, 250 μL of DMEM was added to each well. The following day, 2 μg/mL Shh (464-SH-025/CF, R&D systems, Minneapolis, MN, USA) or 100 ng/mL Wnt‐3a (1324-WN, R&D systems, Minneapolis, MN, USA) were added to the medium. Three days after transduction, total RNA was extracted with RNeasy (QIAGEN, Hilden, Germany), and reverse transcription was performed with a PrimeScript RT Reagent Kit with gDNA Eraser (TakaraBio, Shiga, Japan). cDNA was amplified with TaKaRa Ex Taq (RR001A, TaKaRa Bio Inc., Otsu, Japan) and PrimeTime qPCR probe assays (Integrated DNA Technologies, Coralville, IA, USA). qPCR primers and probes for *Gli1* (Mm.PT.58.11933824), *Axin2* (Mm.PT.58.8726473), *Lss* (Mm.PT.58.41802559), and *Gapdh* (Mm.PT.39a.1) were used. qPCR reactions were cycled using StepOnePlus (Sigma-Aldrich, St. Louis, MO, USA) with standard conditions.

(TIF)

###### 

Click here for additional data file.

###### Variant filtering strategy.

(XLSX)

###### 

Click here for additional data file.

###### Mutations in *LSS*.

(XLSX)

###### 

Click here for additional data file.

###### Laboratory results of the patients with LSS biallelic mutations and unaffected family members in this study.

(XLSX)

###### 

Click here for additional data file.

###### Genotype distribution of neonatal mice born from *Lss*^*wild/flox*^-*Keratin14* male and *Lss*^*flox/flox*^ female mice.

(XLSX)

###### 

Click here for additional data file.

###### MS parameters used for LC-MS/MS analysis.

(DOCX)

###### 

Click here for additional data file.

###### Primers and probes.

The forward primers of *Lss tm1a*, *Lss tm1c*, and *Lss tm1d* were the same. The existence of the *Pax6-Cre* allele was confirmed using generic Cre primers and a probe.

(DOCX)

###### 

Click here for additional data file.
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23 Sep 2019

Dear Dr Kikuchi,

Thank you very much for submitting your Research Article entitled \'Metabolic and pathologic profiles of human LSS deficiency recapitulated in mice\' to PLOS Genetics. Your manuscript was fully evaluated at the editorial level and by independent peer reviewers. The reviewers appreciated the attention to an important problem, but raised some substantial concerns about the current manuscript. Based on the reviews, we will not be able to accept this version of the manuscript, but we would be willing to review again a much-revised version. We cannot, of course, promise publication at that time.

Should you decide to revise the manuscript for further consideration here, your revisions should address the specific points made by each reviewer. We will also require a detailed list of your responses to the review comments and a description of the changes you have made in the manuscript.

If you decide to revise the manuscript for further consideration at PLOS Genetics, please aim to resubmit within the next 60 days, unless it will take extra time to address the concerns of the reviewers, in which case we would appreciate an expected resubmission date by email to <plosgenetics@plos.org>.

If present, accompanying reviewer attachments are included with this email; please notify the journal office if any appear to be missing. They will also be available for download from the link below. You can use this link to log into the system when you are ready to submit a revised version, having first consulted our [Submission Checklist](http://journals.plos.org/plosgenetics/s/submit-now#loc-submission-checklist).

To enhance the reproducibility of your results, we recommend that you deposit your laboratory protocols in protocols.io, where a protocol can be assigned its own identifier (DOI) such that it can be cited independently in the future. For instructions see our [guidelines](http://journals.plos.org/plosgenetics/s/submission-guidelines#loc-materials-and-methods).

Please be aware that our [data availability policy](http://journals.plos.org/plosgenetics/s/data-availability) requires that all numerical data underlying graphs or summary statistics are included with the submission, and you will need to provide this upon resubmission if not already present. In addition, we do not permit the inclusion of phrases such as \"data not shown\" or \"unpublished results\" in manuscripts. All points should be backed up by data provided with the submission.

While revising your submission, please upload your figure files to the [Preflight Analysis and Conversion Engine](http://pace.apexcovantage.com/) (PACE) digital diagnostic tool.  PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email us at <figures@plos.org>.

PLOS has incorporated [Similarity Check](http://www.crossref.org/crosscheck.html), powered by iThenticate, into its journal-wide submission system in order to screen submitted content for originality before publication. Each PLOS journal undertakes screening on a proportion of submitted articles. You will be contacted if needed following the screening process.

To resubmit, use the link below and \'Revise Submission\' in the \'Submissions Needing Revision\' folder.

\[LINK\]

We are sorry that we cannot be more positive about your manuscript at this stage. Please do not hesitate to contact us if you have any concerns or questions.

Yours sincerely,

Luke Engelking

Guest Editor

PLOS Genetics

Gregory Barsh

Editor-in-Chief

PLOS Genetics

All three reviewers were enthusiastic about the major findings of this manuscript. However, a number of issues were identified that will require revision and/or clarification.  These issues will need to be addressed in a point-by-point rebuttal.  Lastly, the following issues in particular may require additional experimental data:

\- Photomicrographs of the hair and ocular structures in addition to the lens

\- Measurements of sterol intermediates

\- Gene and or protein expression data exploring which signaling pathways, such as Wnt or Hh-related pathways, are impacted by LSS deficiency

\- Inclusion of the suggested controls for the transfection experiments in hela cells

\- Methods used for lanosterol and 2,3-epoxysqualene quantification

Reviewer\'s Responses to Questions

**Comments to the Authors:**

**Please note here if the review is uploaded as an attachment.**

Reviewer \#1: The authors submit an interesting study whereby they describe two new patients with novel biallelic mutations in lanosterol synthetase (LSS) who exhibit hair and midline structural abnormalities and a concomitant increase in the substrate:product (S-2,3-epoxysqualene:lanosterol) ratio secondary to an enzymatic block. Additionally, the authors generate tissue-specific LSS-deficient mouse lines with hair/skin and lens abnormalities; the skin from these tissue-specific LSS-deficient mice demonstrate increased S-2,3-epoxysqualene:lanosterol ratios which may alter normal skin homeostasis and hair follicle cycling. The authors provide extensive data throughout the manuscript; however, there are some concerns:

1\) In Figure 1g, the authors illustrate the S-2,3-epoxysqualene:lanosterol ratio from the sebum of the affected patients, their unaffected family members, and controls. Given that cholesterol is essential in the formation of an intact skin barrier, it would be beneficial to show the values of all sterol intermediates and cholesterol in the sebum in these groups since one can speculate that these skin and hair abnormalities may be due to either a deficiency of cholesterol, a buildup of toxic intermediates, or both.

2\) In addition to the high magnification photomicrograph in Figure 1e, a lower magnification photomicrograph of the hair follicles is needed to assess the extent of hair follicle pathology.

3\) As stated above in Concern 1, values for the remainder of the sterol intermediates and cholesterol would be useful in explaining the pathophysiology seen in the LSSf/f-K14 mice illustrated in Figure 2.

4\) Have the authors considered treating the 4-week-old tamoxifen-treated LSSf/f-K14ERT mice that show hair loss and skin abnormalities with statins and/or cholesterol + statins? As the authors suggest in the Discussion, this therapy may reduce these intermediates and reverse the pathology seen in these mice, particularly since the hair follicle cycles continuously throughout the majority of a mammal's lifetime.

5\) Figure 4 depicts the lens pathology seen in mice with LSS deficiency restricted to the lens. From the photomicrographs shown in Figure 4b, there appears to be pathology within other ocular/intraocular structures, such as within the cornea and retina, than in just the lens. Given Pax6-Cre is expressed during early eye development, loss of LSS within other ocular/intraocular tissues may not be surprising. It would be interesting to determine if the LSSf/f-Pax6 mice have retinal or other ocular/intraocular abnormalities besides those of the lens. Lastly, the authors do not state the age of these mice and do not show the LC-MS/MS data of lens or other ocular structures.

6\) Additional points include:

-Line 135: Is the variant supposed to be p.Arg177Gln instead of p.Arg177Glu?

-Line 226: Should it be "increased ratio of substrate to product" instead of decreased?

-The flow of the overall manuscript is rather choppy at times and could use proofreading by a native English speaker for better flow and readability.

Overall, the manuscript is interesting and not only provides more clarification of the tissue-specific pathophysiology seen in these malformation syndromes but also hints at diagnostic assays/therapeutic interventions for LSS deficiency.

Reviewer \#2: In the manuscript entitled \"Metabolic and pathologic profiles of human LSS deficiency recapitulated in mice \", the authors demonstrate disruption of lanosterol synthetase in an inducible mouse model of LSS deficiency results in biochemical deficits and tissue specific changes present within affected human subjects. The work presented within the manuscript is important to the fields of cholesterol biosynthesis defects, rare disease research, and epidermal function. While the authors nicely demonstrate the identification of defined mutations within a small patient cohort of LSS deficiency and recapitulate some of the tissue deficits within a newly derived mouse model, the data presented are not likely of broad enough scientific significance for acceptance in PLOS Genetics. A significant advancement forward for LSS deficiency, such as identification of causative pathways downstream of LSS mutation or amelioration of pathological findings, would greatly enhance the significance of the manuscript.

Concerns related to the manuscript are detailed below.

1\. While the methodology utilized within the manuscript is solid, the data presented, including generation of an inducible Lss mouse model, is largely descriptive. While the inducible Lss mouse is an exciting development for elucidating the pathological mechanisms subsequent to Lss disruption, the addition of mechanistic data is really needed. Are there specific signaling pathways subsequent to Lss deletion that are pathogenic?

2\. It's not clear the significance of the experiments detailing FLAG-tagged LSS mutations and changes in protein expression of specific mutants, particularly in HeLa cells that are demonstrated to already express LSS protein. How a transient transfection of a plasmid containing a mutant cDNA for LSS leads to decreased expression of native LSS is confusing. Further, why specific mutations affect this versus others is similarly confusing. Controls for this experiment for expression levels of the plasmids in an LSS null cell line would be critical.

3\. The clinical findings from the two subjects identified are similar but not identical to the K14 mouse model used. The presence of cleft palate, midline anomalies, and corpus collosum agenesis in particular would not be affected by K14-Cre mediated deletion of Lss. Are these deficits present in the newly created Lss mutant mouse if a constitutive or embryonic Cre-driver used?

4\. The quantitation and detection of sterols is not clearly defined. I believe there are typos within the methods, including what temperature was utilized for compound ionization. Further, how the compounds of interest were identified (i.e. through comparison to a known standard?) was performed. The number of samples analyzed as biological vs. technical replicates is also not clear. Further, the explanation regarding detection of lanosterol and 2,3-epoxysqualene in plasma vs. sebum of patients is unclear. It's not clear why lanosterol would be detected.

5\. For the early lethality of the Lss mouse presumably associated with dehydration, it would be of interest to know if lethality of the mouse could be prevented by administration of fluids. Further, if this is the presumed cause of death and the identified patients clearly have epidermal loss of Lss, it's unclear why their lifespans are extended in comparison to the mouse.

Reviewer \#3: This manuscript by Wada et al. is a carefully crafted insight into LSS deficiency. The authors identified two sibling patients with hypotrichosis and other abnormalities, and performed exome sequencing leading to the identification of LSS mutations as the likely cause. Consistent with this, they found an increase in the substrate of LSS ((S)-2,2-epoxysqualene) in sebum from the patients -- previous efforts had not been able to confirm a lack of LSS activity. They then made skin and lens-specific Lss-deficient mice to show that LSS deficiency results in similar skin problems and cataracts, as indicated in humans. This work is the first to confirm that a lack of LSS activity in the affected tissues leads to the specific phenotypes observed in patients with LSS deficiency. This is significant and has important implications for the treatment of this disease, as well as broader implications for other cholesterol synthesis enzyme defects associated with diseases. I have only minor comments, which I list below.

Minor comments:

1\. Page 5, line 64: please rephrase "Cholesterol is an essential nutrient" as this is not strictly correct.

2\. Supp Fig 1: Only LBR is listed -- please also include DHCR14 (these enzymes catalyse the same step). Zymosterol is listed twice -- it should be zymostenol in the Kandutsch-Russell pathway. Dehydrodesmosterol should be 7-dehydrodesmosterol. Dihydrolanosterol is, I think, more commonly referred to as 24,25-dihydrolanosterol.

3\. Page 5, line 73-74: The sentence about the 24 patients is confusing -- suggest rephrasing to "Out of 24 patients, all had either cataracts (5/24) or hypotrichosis (20/24), and one had both".

4\. Page 5, line 86: Should this be a citation to the publication by Dickinson et al 2016 Nature as indicated on the website?

5\. Page 9, line 151-152: The sentence about W581R and G588S is confusing -- consider revising or removing.

6\. Fig 2c: The authors note that lanosterol was undetectable in the skin of these mice, but in humans, and the tamoxifen-inducible knockout mice, they were able to detect lanosterol and present a ratio. Could the authors speculate on why lanosterol was not detectable? Further, was there any difference in the levels of cholesterol itself?

7\. Fig 2b, S9 Fig: Can these be presented with individual data points instead, as in other graphs?

8\. Fig 2d: Was the decrease in body weight of Lssf/f-K14 mice significantly different from the others? This should be indicated in the text/figure.

9\. The figure legends include some results which may be better placed in the main text -- please consider revising.

10\. Fig 4c: The authors indicate that lanosterol levels are not significantly different -- could the authors comment on why they are unchanged? Are total cholesterol levels changed?

11\. S7 Fig: What is the large peak? Is it cholesterol?

12\. S12 Fig: What happens if control mice are treated with a topical application of 4-hydroxytamoxifen?

13\. Some of the supplementary material could be included in the main figures e.g. S5, S7, S9 -- I will leave this for the authors to consider.

Typographical/visual comments:

1\. Page 5, line 66: cholesterol and intermediates are "precursors" to vitamin D, etc, rather than "components" of. Please rephrase.

2\. Page 8, line 135: The mutation is mislabelled as Glu -- should be Gln.

3\. Page 13, line 226: Should this be an increased ratio rather than decreased?

4\. In some places, LSS is referred to as lanosterol synthase, but in others it is lanosterol synthetase -- please be consistent.

5\. Page 8, line 145: Please define EB-LCLs (and PBMCs page 18, line 342 and fig 1 legend).

6\. Fig 3b: Please label what the top and bottom pictures represent.

7\. Fig 4a,b,c: For clarity, please consider labelling mouse/lens/H&E/immunohistochemistry.

8\. S4 Fig: Please indicate which patient.

9\. Fig 1f: Please align labels over bands.

\*\*\*\*\*\*\*\*\*\*

**Have all data underlying the figures and results presented in the manuscript been provided?**

Large-scale datasets should be made available via a public repository as described in the *PLOS Genetics* [data availability policy](http://journals.plos.org/plosgenetics/s/data-availability), and numerical data that underlies graphs or summary statistics should be provided in spreadsheet form as supporting information.

Reviewer \#1: Yes

Reviewer \#2: Yes

Reviewer \#3: Yes

\*\*\*\*\*\*\*\*\*\*

PLOS authors have the option to publish the peer review history of their article ([what does this mean?](https://journals.plos.org/plosgenetics/s/editorial-and-peer-review-process#loc-peer-review-history)). If published, this will include your full peer review and any attached files.

If you choose "no", your identity will remain anonymous but your review may still be made public.

**Do you want your identity to be public for this peer review?** For information about this choice, including consent withdrawal, please see our [Privacy Policy](https://www.plos.org/privacy-policy).

Reviewer \#1: No

Reviewer \#2: No

Reviewer \#3: Yes: Laura Sharpe
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\* Please note while forming your response, if your article is accepted, you may have the opportunity to make the peer review history publicly available. The record will include editor decision letters (with reviews) and your responses to reviewer comments. If eligible, we will contact you to opt in or out. \*

Dear Dr Kikuchi,

Thank you very much for submitting your Research Article entitled \'Metabolic and pathologic profiles of human LSS deficiency recapitulated in mice\' to PLOS Genetics. Your manuscript was fully evaluated at the editorial level and by independent peer reviewers. The reviewers appreciated the attention to an important topic but identified some aspects of the manuscript that should be improved.

We therefore ask you to modify the manuscript according to the review recommendations before we can consider your manuscript for acceptance. Your revisions should address the specific points made by each reviewer.

In addition we ask that you:

1\) Provide a detailed list of your responses to the review comments and a description of the changes you have made in the manuscript.

2\) Upload a Striking Image with a corresponding caption to accompany your manuscript if one is available (either a new image or an existing one from within your manuscript). If this image is judged to be suitable, it may be featured on our website. Images should ideally be high resolution, eye-catching, single panel square images. For examples, please browse our [archive](http://www.plosgenetics.org/article/browse/volume). If your image is from someone other than yourself, please ensure that the artist has read and agreed to the terms and conditions of the Creative Commons Attribution License. Note: we cannot publish copyrighted images.

We hope to receive your revised manuscript within the next 30 days. If you anticipate any delay in its return, we would ask you to let us know the expected resubmission date by email to <plosgenetics@plos.org>.

If present, accompanying reviewer attachments should be included with this email; please notify the journal office if any appear to be missing. They will also be available for download from the link below. You can use this link to log into the system when you are ready to submit a revised version, having first consulted our [Submission Checklist](http://journals.plos.org/plosgenetics/s/submit-now#loc-submission-checklist).

While revising your submission, please upload your figure files to the [Preflight Analysis and Conversion Engine](http://pace.apexcovantage.com/) (PACE) digital diagnostic tool. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email us at <figures@plos.org>.

Please be aware that our [data availability policy](http://journals.plos.org/plosgenetics/s/data-availability) requires that all numerical data underlying graphs or summary statistics are included with the submission, and you will need to provide this upon resubmission if not already present. In addition, we do not permit the inclusion of phrases such as \"data not shown\" or \"unpublished results\" in manuscripts. All points should be backed up by data provided with the submission.

PLOS has incorporated [Similarity Check](http://www.crossref.org/crosscheck.html), powered by iThenticate, into its journal-wide submission system in order to screen submitted content for originality before publication. Each PLOS journal undertakes screening on a proportion of submitted articles. You will be contacted if needed following the screening process.

To resubmit, you will need to go to the link below and \'Revise Submission\' in the \'Submissions Needing Revision\' folder.

\[LINK\]

Please let us know if you have any questions while making these revisions.

Yours sincerely,

Luke Engelking

Guest Editor

PLOS Genetics

Gregory Barsh

Editor-in-Chief

PLOS Genetics

Editor comments to author:

Thank you for your revised manuscript, which is now acceptable for publication pending the clarification of the textual description of Fig. S13, as suggested by reviewer 2.

Reviewer\'s Responses to Questions

**Comments to the Authors:**

**Please note here if the review is uploaded as an attachment.**

Reviewer \#1: The authors have extensively addressed all reviewers\' concerns and have added new data to support their findings. Overall, this study is an interesting one; and the data presented here will act as a springboard for further investigations, particularly mechanistic ones, into disorders due to cholesterol biosynthesis defects.

Reviewer \#2: In the manuscript entitled \"Metabolic and pathologic profiles of human LSS deficiency recapitulated in mice \", the authors demonstrate disruption of lanosterol synthetase in an inducible mouse model of LSS deficiency results in biochemical deficits and tissue specific changes present within affected human subjects. The work presented within the manuscript is important to the fields of cholesterol biosynthesis defects, rare disease research, and epidermal function. The authors nicely demonstrate the identification of defined mutations within a small patient cohort of LSS deficiency and recapitulate some of the tissue specific deficits within a newly derived Lss epidermal-specific knockout mouse.

From a positive perspective, the authors attempted to answer the issues raised by reviewers after the initial submission. The manuscript is improved from the first submission and the authors have added some additional supplementary data, attempted to answer biochemical and signaling questions posed by reviewers, and clarified the text. However, as noted in my initial review, I still believe the work as presented is lacking a significant advancement forward for LSS deficiency. Though the study has demonstrated loss of LSS function within the epidermis results in neonatal lethality and lens specific Lss knockout induces tissue phenotypes, there is still a lack of data demonstrating the mechanisms downstream of Lss loss leading to lethality or tissue phenotypes.

\- Biochemically, there appears to be no loss of epidermal cholesterol (Fig S9) which would mechanistically explain the barrier deficiency presented in Figure 2. It's possible 2,3-epoxysqualene accumulation at picomolar/mg levels as demonstrated in Figure 2 could exert oxidative stress on the epidermis, inducing apoptosis or lipid peroxidation. However, this is not explored. While I am distinctly aware of the difficulty with these types of analyses in limited tissue samples, these are critical data.

\- While the authors did test LSS effects on SHH and Wnt signaling in MEF isolations, no deficits were identified. It's not clear if this lack of effect is due to a true maintenance of signaling in the absence of LSS activity or limitations due to the assay. Possible explanations that come to mind include cell type of choice representing mesodermal vs ectodermal lineage of the epidermis, method of LSS deletion via AAV1 (though the qPCR analysis demonstrates fairly efficient knockdown of Lss), or limitations of the qPCR assay used. The methodology suggests MEFs were isolated with FBS, AAV1 transduction performed, and RNA isolated 3 days post-transduction. Was the biochemical defect confirmed at this time point? Further, since both SHH and Wnt signaling utilize morphogen gradients through ligand secretion by one cell type and generally ligand-responsive signaling in a separate cell, I believe IHC analyses specific to the epidermis for SHH and/or Wnt responsiveness would be a better assay of choice. However, based on a lack of cholesterol loss within the epidermis (Fig S9), it\'s not clear if either of these pathways would be substantially disrupted in this tissue.

In my view, any of these three outcomes would represent a significant advancement for Lss deficiency:

1\) identification of causative pathways downstream of LSS loss

2\) determining the biochemical changes responsible for the pathological findings

3\) correction (or prevention) of pathological findings.

Any of these would be acceptable. But as the work currently stands and in comparison to previously published studies on LSS, the major finding of epidermal or lens-specific loss of Lss with confusing biochemistry (no cholesterol loss) and no well-defined mechanism is troublesome.

Minor issues to clarify related to newly presented data

S13 - "There were fewer retinal ganglion cells in Lssf/f-Pax6 mice than there were in Lssf/f mice. In contrast, the outer nuclear layers were not found to be different between Lssf/f-Pax6 and Lssf/f mice."

" -- this is not actually quantified or explained well. What does 'different' mean?

Reviewer \#3: The authors have done their best to address comments by the reviewers. The measurement of additional sterols would indeed be interesting, but is quite difficult and so it is understandable that this has not been as extensive as hoped.

\*\*\*\*\*\*\*\*\*\*

**Have all data underlying the figures and results presented in the manuscript been provided?**

Large-scale datasets should be made available via a public repository as described in the *PLOS Genetics* [data availability policy](http://journals.plos.org/plosgenetics/s/data-availability), and numerical data that underlies graphs or summary statistics should be provided in spreadsheet form as supporting information.

Reviewer \#1: Yes

Reviewer \#2: Yes

Reviewer \#3: Yes

\*\*\*\*\*\*\*\*\*\*

PLOS authors have the option to publish the peer review history of their article ([what does this mean?](https://journals.plos.org/plosgenetics/s/editorial-and-peer-review-process#loc-peer-review-history)). If published, this will include your full peer review and any attached files.

If you choose "no", your identity will remain anonymous but your review may still be made public.

**Do you want your identity to be public for this peer review?** For information about this choice, including consent withdrawal, please see our [Privacy Policy](https://www.plos.org/privacy-policy).

Reviewer \#1: No

Reviewer \#2: No

Reviewer \#3: No
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Dear Dr Kikuchi,

We are pleased to inform you that your manuscript entitled \"Metabolic and pathologic profiles of human LSS deficiency recapitulated in mice\" has been editorially accepted for publication in PLOS Genetics. Congratulations!

Before your submission can be formally accepted and sent to production you will need to complete our formatting changes, which you will receive in a follow up email. Please be aware that it may take several days for you to receive this email; during this time no action is required by you. Please note: the accept date on your published article will reflect the date of this provisional accept, but your manuscript will not be scheduled for publication until the required changes have been made.

Once your paper is formally accepted, an uncorrected proof of your manuscript will be published online ahead of the final version, unless you've already opted out via the online submission form. If, for any reason, you do not want an earlier version of your manuscript published online or are unsure if you have already indicated as such, please let the journal staff know immediately at <plosgenetics@plos.org>.

In the meantime, please log into Editorial Manager at <https://www.editorialmanager.com/pgenetics/>, click the \"Update My Information\" link at the top of the page, and update your user information to ensure an efficient production and billing process. Note that PLOS requires an ORCID iD for all corresponding authors. Therefore, please ensure that you have an ORCID iD and that it is validated in Editorial Manager. To do this, go to 'Update my Information' (in the upper left-hand corner of the main menu), and click on the Fetch/Validate link next to the ORCID field.  This will take you to the ORCID site and allow you to create a new iD or authenticate a pre-existing iD in Editorial Manager.

If you have a press-related query, or would like to know about one way to make your underlying data available (as you will be aware, this is required for publication), please see the end of this email. If your institution or institutions have a press office, please notify them about your upcoming article at this point, to enable them to help maximise its impact. Inform journal staff as soon as possible if you are preparing a press release for your article and need a publication date.

Thank you again for supporting open-access publishing; we are looking forward to publishing your work in PLOS Genetics!

Yours sincerely,

Luke Engelking

Guest Editor

PLOS Genetics

Gregory Barsh

Editor-in-Chief

PLOS Genetics

[www.plosgenetics.org](http://www.plosgenetics.org)

Twitter: \@PLOSGenetics

\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\--

Comments from the reviewers (if applicable):

\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\--

**Data Deposition**

If you have submitted a Research Article or Front Matter that has associated data that are not suitable for deposition in a subject-specific public repository (such as GenBank or ArrayExpress), one way to make that data available is to deposit it in the [Dryad Digital Repository](http://www.datadryad.org). As you may recall, we ask all authors to agree to make data available; this is one way to achieve that. A full list of recommended repositories can be found on our [website](http://journals.plos.org/plosgenetics/s/data-availability#loc-recommended-repositories).

The following link will take you to the Dryad record for your article, so you won\'t have to re‐enter its bibliographic information, and can upload your files directly: 

<http://datadryad.org/submit?journalID=pgenetics&manu=PGENETICS-D-19-01355R2>

More information about depositing data in Dryad is available at <http://www.datadryad.org/depositing>. If you experience any difficulties in submitting your data, please contact <help@datadryad.org> for support.

Additionally, please be aware that our [data availability policy](http://journals.plos.org/plosgenetics/s/data-availability) requires that all numerical data underlying display items are included with the submission, and you will need to provide this before we can formally accept your manuscript, if not already present.

\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\--

**Press Queries**

If you or your institution will be preparing press materials for this manuscript, or if you need to know your paper\'s publication date for media purposes, please inform the journal staff as soon as possible so that your submission can be scheduled accordingly. Your manuscript will remain under a strict press embargo until the publication date and time. This means an early version of your manuscript will not be published ahead of your final version. PLOS Genetics may also choose to issue a press release for your article. If there\'s anything the journal should know or you\'d like more information, please get in touch via <plosgenetics@plos.org>.

10.1371/journal.pgen.1008628.r006
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PGENETICS-D-19-01355R2

Metabolic and pathologic profiles of human LSS deficiency recapitulated in mice

Dear Dr Kikuchi,

We are pleased to inform you that your manuscript entitled \"Metabolic and pathologic profiles of human LSS deficiency recapitulated in mice\" has been formally accepted for publication in PLOS Genetics! Your manuscript is now with our production department and you will be notified of the publication date in due course.

The corresponding author will soon be receiving a typeset proof for review, to ensure errors have not been introduced during production. Please review the PDF proof of your manuscript carefully, as this is the last chance to correct any errors. Please note that major changes, or those which affect the scientific understanding of the work, will likely cause delays to the publication date of your manuscript.

Soon after your final files are uploaded, unless you have opted out or your manuscript is a front-matter piece, the early version of your manuscript will be published online. The date of the early version will be your article\'s publication date. The final article will be published to the same URL, and all versions of the paper will be accessible to readers.

Thank you again for supporting PLOS Genetics and open-access publishing. We are looking forward to publishing your work!

With kind regards,

Kaitlin Butler

PLOS Genetics

On behalf of:

The PLOS Genetics Team

Carlyle House, Carlyle Road, Cambridge CB4 3DN \| United Kingdom

<plosgenetics@plos.org> \| +44 (0) 1223-442823

[plosgenetics.org](http://plosgenetics.org) \| Twitter: \@PLOSGenetics

[^1]: The authors have declared that no competing interests exist.
